Search clinical trials for: BCR-ABL TKI

Total 547 results

Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Non-small Cell Lung Cancer | EGFR Gene Mutation

China
Centro Nacional de Investigaciones Oncologicas...
M.D. Anderson Cancer Center; Hospital Universitari de Bellvitge; Hospital Universitario...

Terminated

Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

Solid Tumors

Spain
Spanish Lung Cancer Group

Completed

T790M Mutation Testing in Blood by Different Methodologies

NSCLC Stage IV

Spain
Safaa AA Khaled

Unknown

Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm

Myeloproliferative Neoplasm
Catholic University of the Sacred Heart

Completed

Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors

Renal Cell Cancer | Diarrhea Caused by Drug (Disorder)

Italy
Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Leukemia

United States
Novartis Pharmaceuticals

Terminated

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Non-Small Cell Lung Cancer

Italy, Singapore, Spain, Germany, Korea, Republic of, United States, Belgium, France, Netherlands, Japan
Guangdong Association of Clinical Trials

Unknown

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Non-small Cell Lung Cancer

China
Geneplus-Beijing Co. Ltd.
Shanghai Chest Hospital

Completed

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Lung Neoplasms | Adenocarcinoma of Lung | Lung Cancer, Nonsmall Cell | Squamous Cell Lung Cancer

China
Asan Medical Center

Completed

Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258

Gastrointestinal Stromal Tumors

Korea, Republic of
GenesisCare USA

Terminated

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®)- for Maintaining Bowel Regularity in Patients With GI Toxicity From Any Combination of Therapy Including Tyrosine Kinase Inhibitors (TKI)

Diarrhea

United States
Asan Medical Center
Novartis

Completed

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Gastric Cancer

Korea, Republic of
Gesellschaft fur Medizinische Innovation - Hamatologie...
Crolll Gmbh

Completed

Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation (Crescendo)

Chronic Myelogenous Leukemia (CML)

Germany
Shanghai Chest Hospital

Completed

Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy

Lung Cancer

China
Shanghai Chest Hospital

Completed

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Lung Adenocarcinoma | EGFR Activating Mutation
Baodong Qin

Unknown

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

NSCLC Stage IV | Anlotinib | EGFR T790M-negative | JS001

China
M.D. Anderson Cancer Center
Novartis

Completed

TKI258 in Castrate Resistant Prostate Cancer

Prostate Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Leukemia

China
Clovis Oncology, Inc.

Terminated

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of, United States, France, Germany, Netherlands, Australia, Spain, Taiwan, United Kingdom, Italy
M.D. Anderson Cancer Center
Novartis

Completed

TKI258 for Metastatic Inflammatory Breast Cancer Patients

Breast Cancer

United States
Pfizer

Completed

Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC

Renal Cell Carcinoma

Turkey
Novartis Pharmaceuticals

Terminated

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Advanced Non Small Cell Lung Cancer (NSCLC)

France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
Medical University Innsbruck
European Union

Completed

MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT

Gastrointestinal Stromal Tumors

Austria
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Hospices Civils de Lyon

Completed

Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia (NILOPEG)

Chronic Myelogenous Leukemia

France
Cancer Institute and Hospital, Chinese Academy...

Unknown

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Non-Small Cell Lung Cancer Metastatic

China
Shenzhen People's Hospital

Unknown

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (AFLC)

NSCLC | Apatinib | EGFR-TKI

China
M.D. Anderson Cancer Center
Novartis

Terminated

Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Prostate Cancer

United States
Hellenic Oncology Research Group

Unknown

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

Non Small Cell Lung Cancer

Greece
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Non-small Cell Lung Cancer | Brain Metastases

China
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
Central European Society for Anticancer Drug Research

Completed

Sequential Therapy in Metastatic Renal Cell Carinoma (BERAT)

Metastatic Renal Cell Carcinoma

Germany
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Withdrawn

A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

NSCLC

China
Sierra Oncology, Inc.

Terminated

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

United States
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; Chia Tai Tianqing Pharmaceutical... and other collaborators

Unknown

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Non-Small-Cell Lung

China
Haihua Yang

Unknown

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Beijing Chest Hospital

Unknown

The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Emory University

Terminated

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Xinqiao Hospital of Chongqing

Terminated

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC (CERTAIN)

Non Small Cell Lung Cancer

China
Incyte Biosciences International Sàrl

Withdrawn

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

BCR-ABL Positive Acute Lymphoblastic Leukemia

Germany, France, Czechia
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

Leukemia

United States
University of Virginia
Novartis Pharmaceuticals

Completed

Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma

United States
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Astellas Pharma Inc

Terminated

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Japan
Affiliated Cancer Hospital & Institute of Guangzhou...

Unknown

Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)

Hepatitis B | Non Small Cell Lung Cancer

China
Beth Israel Deaconess Medical Center
National Institutes of Health (NIH); Teva Pharmaceuticals USA

Terminated

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

United States
Il-Yang Pharm. Co., Ltd.

Completed

Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Philadelphia Chromosome

India, Korea, Republic of, Thailand

3

Subscribe